Rare Daily Staff
Genfit, which is developing therapies for metabolic and liver diseases, said that it appointed Pascal Prigent, Genfit’s executive vice president of marketing and commercial development, as CEO.
Prigent will replace Jean-François Mouney, who will remain chairman of the board. Mouney will step down as CEO September 16 and had recommended the board appoint Prigent as his replacement.
Prigent joined Genfit in May 2018 and has been a key member of Genfit’s executive committee. Prigent is credited with establishing global collaborators and consultants in preparation for the potential commercialization the company’s first products, including its experimental therapy for primary biliary cholangitis, a rare disease that leads to the destruction of the bile ducts and causes cirrhosis. He has more than 20 years of experience in the pharmaceutical industry, including international management roles with Eli Lilly and GlaxoSmithKline.
After two decades at the helm working to develop Genfit, Mouney said his decision to step down was personal.
“I’ve asked Pascal to accept the CEO position because I’m convinced he is best positioned to oversee our future corporate growth,” said Jean-François Mouney, co-founder, chairman and CEO of Genfit. “Pascal has the right experience, the right skills, the right mindset and the right personality to help build Genfit.”
Photo: Pascal Prigent, Genfit’s executive vice president of marketing and commercial development, who will become CEO later this month.